Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the "Meeting"). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.

The Company is also pleased to announce that, effective October 1, 2026, the Company’s legal name will be changed from "Cybin Inc." to "Helus Pharma Inc.". The legal name change follows the Company’s adoption of the business name "Helus Pharma" on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company.

1. Appointment of Auditor

Zeifmans LLP was appointed auditor of Helus until the next annual meeting of shareholders at renumeration to be fixed by the directors of Helus. Voting results are set out below:

Votes ForVotes Withheld
#%#%
46,084,00499.207368,5930.793



2. Number of Directors

The special resolution to set the number of directors of Helus at eight was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes ForVotes Against
#%#%
46,139,33399.326313,2630.674



3. Name Change

The special resolution to change the name of the Company from "Cybin Inc." to "Helus Pharma Inc." or such other name as may be approved by the directors, was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:

Votes ForVotes Against
#%#%
46,134,60299.315317,9940.685



4. Election of Directors

Each of the nominees for election as director listed in Helus’s management information circular dated August 18, 2026 were elected as directors of Helus for the ensuing year or until their successors are elected or appointed. Voting results are set out below:

 

Votes ForVotes Withheld 
#%#% 
Theresa Firestone31,992,42999.239245,3710.761
Grant Froese32,147,16099.71990,6400.281
Paul Glavine23,072,24871.5699,165,55228.431
Michael Halstead23,089,89071.6249,147,91028.376
Eric Hoskins30,895,23595.8351,342,5654.165
Mark Lawson32,156,08299.74781,7180.253
Freda Lewis-Hall23,063,32771.5419,174,47328.459
Eric So22,795,63471.3219,166,47128.679